Journal of Psychoactive Drugs
August 21, 2023
Caroline Rutherford, Austin Le, Joseph J Palamar et al.
2 citations
Few epidemiological studies have focused on seasonal variation in the use of common psychedelics and party drugs among nightclub and festival attendees, typically those who attend electronic dance music (EDM) events. We sought to determine whether the use of different drug types varies seasonally within this population. Across 15 seasons from summer 2017 through fall 2022, we surveyed 3,935...
Drug and Alcohol Dependence Reports
August 10, 2023
Rebecca D. Hill, Ritu A. Shetty, Nathalie Sumien et al.
4 citations
Aims: Benzofurans are used recreationally, due their ability to cause psychostimulant and/or entactogenic effects, but unfortunately produce substantial adverse effects, including death. Three benzofurans 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-APDB), 5-(2-aminopropyl)-2,3-dihydrobenzofuran (5-MAPB) and 6-(2-aminopropyl) benzofuran (6-APB) were tested to determine their behavioral effects in...
Metabolomics : Official journal of the Metabolomic Society
August 2, 2023
Ross Van de Wetering, Jan A Vorster, Sophie Geyrhofer et al.
4 citations
Metabolomics produces vast quantities of data but determining which metabolites are the most relevant to the disease or disorder of interest can be challenging. This study sought to demonstrate how behavioral models of psychiatric disorders can be combined with metabolomics research to overcome this limitation. We designed a preclinical, untargeted metabolomics procedure, that focuses on the...
Frontiers in Psychiatry
July 11, 2023
Gniewko Więckiewicz, Iga Stokłosa, Maciej Stokłosa et al.
2 citations
Introduction Attention-deficit/hyperactivity disorder (ADHD) was originally treated as a neurodevelopmental disorder that occurs mainly in children and tends to diminish or disappear with age, but we now know that symptoms persist into adulthood in over 50% of ADHD patients. Undiagnosed individuals often turn to psychoactive substance to minimize the negative aspects of functioning and improve...
Neuroscience & Biobehavioral Reviews
July 1, 2023
Manoj K. Doss, Harriet de Wit, David A Gallo
30 citations
Psychoactive drugs modulate learning and emotional processes in ways that could impact their recreational and medical use. Recent work has revealed how drugs impact different stages of processing emotional episodic memories, specifically encoding (forming memories), consolidation (stabilizing memories), and retrieval (accessing memories). Drugs administered before encoding may preferentially...
Journal of Affective Disorders
July 1, 2023
Allison A. Feduccia, Gabby Agin-Liebes, Collin M. Price et al.
38 citations
Psychedelic substances are under investigation in several drug development programs. Controlled clinical trials are providing evidence for safe and effective use of psychedelic therapies for treating mental health conditions. With the anticipated FDA approval of MDMA-assisted therapy for posttraumatic stress disorder in 2023 and psilocybin therapy for depression disorders soon after, now is the...
Mental Health Weekly
June 30, 2023
Valerie A. Canady
Observing that designing clinical studies to evaluate the safety and effectiveness of psychedelic substances presents a number of unique challenges that require careful consideration to the industry, the U.S. Food and Drug Administration (FDA) last month issued, for the first time, draft guidance for conducting clinical trials with psychedelic drugs such as psilocybin and MDMA (ecstasy).
June 29, 2023
Torsten Passie
Abstract This chapter provides an overview of the early, rather unknown, phase of MDMA as a recreational drug. MDMA was first detected by scientists in a forensic laboratory in 1970, and then a few more times up until 1976. A previously unknown document of the United States DEA has been used to describe these early detections. The evidence shows that up until 1976, the distribution of MDMA was...
The History of MDMA
June 29, 2023
Torsten Passie
Abstract The American chemist Alexander T. Shulgin played a significant role in the ‘rediscovery’ of MDMA in the 1970s. In 1960, an experience with mescaline inspired Shulgin to undertake research with psychoactive drugs. He subsequently synthesized psychoactive chemicals and tested them on himself and a group of others. In the early 1960s, Shulgin studied the chemistry of nutmeg: chemical...
Psychiatric News
June 28, 2023
Terri D’arrigo
Back to table of contents Previous article Next article Annual MeetingFull AccessExperts Offer Tips on Talking With Patients About PsychedelicsTerri D’ArrigoTerri D’ArrigoSearch for more papers by this authorPublished Online:28 Jun 2023https://doi.org/10.1176/appi.pn.2023.07.7.51AbstractPsychedelics differ from one another in their mechanism of action and potential effects on the body and mind....